



The Corporate Strategic Intelligence you need!



Press Release

Grez-Doiceau, Belgium, and Lalaye, France, May 13, 2013

## **CSINTELL AND CHRYSALIUM CONSULTING FORM AN ALLIANCE TO PROVIDE UNIQUE STRATEGIC INTELLIGENCE FOR THE MEDICAL RADIATION INDUSTRY WORLDWIDE**

CSIntell, founded by Paul-Emmanuel Goethals and Chrysalium Consulting, founded by Richard Zimmermann announced today they have formed an alliance to provide unique Strategic Intelligence for the Medical Radiation Industry worldwide. The alliance branded as MEDraysintell, aims at further reinforcing the quality of services and better support the decisional process of their customers.



The MEDraysintell alliance will focus on providing high added value Strategic Intelligence to their respective clients by combining unique experiences in Radiotherapy and Nuclear Medicine. The alliance will be able to deliver to companies active in this industry, such as manufacturers of radiopharmaceuticals or therapeutic radioisotopes or

vendors of equipment and software as well as investors interested by this industry, unique services helping them to better understand the markets, the competitive environment, as well as the potential M&A and technology development.

A first outcome of this alliance will be the release before end of 2013 of a report on opportunities in Nuclear Medicine covering two key subjects of interest: development of new molecules in Radiopharmacy and new equipment in Nuclear Medicine, including cyclotrons, scanners, and others, as well as a review of the numerous companies active in this field.

The Medical Radiation industry is segmented into two main markets: Radiation Therapy and Nuclear Medicine. Radiation Therapy encompasses such markets as Radiotherapy (Linear accelerators, IMRT, IGRT, Cobalt-60), proton therapy, brachytherapy and radioisotopes used for therapy. Nuclear Medicine includes PET and SPECT radiopharmaceuticals and scanners used for diagnostic purpose and radiolabeled substances for therapeutic applications. The Medical Radiation industry also includes cyclotrons, dosimetry and software related to therapy and diagnosis.

“With Richard we have together 40 years of experiences in radiotherapy, particle therapy and nuclear medicine. He brings his extensive scientific knowledge of the industry and network connections to combine with my experience in consulting, strategic intelligence and investors relations with a unique understanding of medical/healthcare markets”, said Paul-Emmanuel Goethals, Founder & Management Consultant at CSIntell.

“Together we will be capable to help our customers better understand the Medical Radiation market, in terms of new technical-scientific development and in terms of market evolution. This alliance becomes a unique expert driven structure, joining Paul-Emmanuel’s expertise in Proton Therapy and business development and my knowledge in nuclear medicine and radiopharmaceuticals industrialization”, said Dr. Richard Zimmermann, Founder & Senior Consultant at Chrysalium Consulting.



The Corporate Strategic Intelligence you need!



#### **About CSIntell**

Paul-Emmanuel Goethals, MBA, founded CSIntell as a new approach to connect Strategic Information needed by Top Executives to business needs, in a concise and understandable way. Paul-Emmanuel holds an MBA from the University of Dallas, Texas, and he has 24 years of experience in consulting, business development, intelligence and investors relations with a unique understanding of medical/healthcare markets. Most recently he was Vice President Business Development & Capital Markets and Special Counsel to the CEO at Eckert & Ziegler Group and he was Director Corporate Business Development & Investor Relations at IBA for 11 years. Please visit us at: [www.csintell.com](http://www.csintell.com)

#### **About Chrysalium Consulting SARL**

Dr. Richard Zimmermann, PhD, founded Chrysalium Consulting in 2012 to support companies in the field of medical applications using radiations, mainly in nuclear medicine (radiopharmaceuticals) with a main focus on business development (evaluation, competition analysis, strategic development, pipeline management) and translational processes (industrialization processes, regulatory constraints and clinical development). Richard holds a PhD degree in organic chemistry, followed by a post-doctoral experience at Georgetown University, Washington DC. He spent his career with pharmaceutical companies (Beecham, Solvay Pharmaceuticals), then in the radiopharmaceutical area as R&D director at CISbio International (later acquired by Schering, then IBA). Between 2006 and 2011, he was in charge of the radiopharmaceutical business development, to create the nuclear medicine product pipeline of the company. He is the founder of Oncidium, a foundation aiming at promoting radiotherapeutics [www.oncidium-life.org](http://www.oncidium-life.org).

#### **Contact**

##### **CSIntell**

**Paul-Emmanuel GOETHALS, MBA**  
Founder, Management Consultant  
Grez-Doiceau, Belgium  
e-mail: [paul@csintell.com](mailto:paul@csintell.com)  
Mobile: +32 491 080 968

##### **Chrysalium Consulting SARL**

**Dr. Richard Zimmermann, PhD**  
Senior Consultant  
Lalaye, France  
email : [richard.zimmermann@chrysalium.com](mailto:richard.zimmermann@chrysalium.com)  
Mobile : +33 6 82 80 06 00